Feb. 23 at 9:40 PM
$ITRM lastly it sounds like they’re getting a lot of scripts coming in, but there is no novel antibiotic competition as of right now, since bluejepa and Pivya are not on the market yet. so that means that they’re getting traction with insurers which means we should be seeing a better full quarter than we saw a partial quarter. otherwise scripts would be down as of today- so now the big question is why does CF not want to talk to us? Is he in the middle of a deal and has been told no talkie?I’m sure he doesn’t like us because we voted no. in retrospect if he had done it right, he would’ve just asked for a reverse split. then he would’ve shared script numbers, then we would have a reason to say yes on some sort of a step-by-step dilution plan. Instead he asked for too much upfront without opening the kimono. he interprets that as we doesn’t want to work with him, but we interpreted it as he’s not being forthcoming with launch info- concept of separate realities I guess.
